Athena Athena

X
[{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"Flu Lab","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Greenlight Biosciences Raises $17M Financing Round to Accelerate Large-Scale Manufacturing of Future COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serum Institute of India and GreenLight Biosciences Multitarget Licensing Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform"},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NIH, GreenLight Biosciences to Collaborate On COVID-19 Vaccine Development for New Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"EpiVax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GreenLight Biosciences Receives Approval to Initiate Phase I\/II Clinical Trial of Covid-19 mRNA Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by GreenLight Biosciences

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            GLB-COV2-043 is a promising booster vaccine candidate component for adult participants who have received the 2-dose priming course of the mRNA BNT162b2 vaccine against COVID-19.

            Lead Product(s): GLB-COV2-043

            Therapeutic Area: Infections and Infectious Diseases Product Name: GLB-COV2-043

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 01, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the collaboration, GreenLight Biosciences and Epivax Therapeutics will design and develop new personalized mRNA-based cancer vaccine candidates using GreenLight and EpiVax Therapeutics technology platforms.

            Lead Product(s): mRNA-based Vaccine

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Vaccine

            Partner/Sponsor/Collaborator: EpiVax

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            GreenLight—in collaboration with the Vaccine Research Center, part of NIH’s National Institute of Allergy and Infectious Diseases—will co-design and test mRNA vaccines against coronaviruses with the goal of developing vaccines that confer a more durable immune response.

            Lead Product(s): mRNA-Based COVID-19 Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Vaccine

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 29, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Serum Institute of India has engaged GreenLight to design three messenger RNA products, including a vaccine for shingles. Serum Institute of India also has an option to expand the relationship further for two additional vaccine or therapeutic targets.

            Lead Product(s): mRNA-based Therapy

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Vaccine

            Partner/Sponsor/Collaborator: Serum Institute of India

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 14, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This round of financing is aimed at establishing a scaled process under cGMP, capable of supporting clinical development and enabling the production of billions of doses of COVID-19 vaccine using GreenLight's proprietary bioprocessing technology.

            Lead Product(s): mRNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Flu Lab

            Deal Size: $17.0 million Upfront Cash: Undisclosed

            Deal Type: Financing May 12, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY